<div class="headers"><div>Figure 1: Time to ﬁrst SARE and rates and rate ratios for severe exacerbations for patients randomised to budesonide or placebo, by baseline asthma symptom frequency(A) Time to first severe asthma-related event (Pinterartion=0-94 p values are for interaction between treatment and baseline symptom frequency subgroup) and (B) rates and rate ratios for severe exacerbations identified by proportion of oral or systemic corticosteroid courses (Pinteract,on=0'll)- SARE=severe asthma-related event.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">0 to 1 symptom days per week</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">>lto £2 symptom days per week</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">>2 symptom days per week</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Hazard ratio</p></td>
<td style='text-align: left;'><p style="" class="">HR 0-54 (95% Cl 034-0-86)</p></td>
<td style='text-align: left;'><p style="" class="">HR 0-60 (95% Cl 0-39-0-93)</p></td>
<td style='text-align: left;'><p style="" class="">HR 0-57 (95% Cl 0-41-0-79)</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">Rate ratio {95% Cl)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">0-48 (038-0-61)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">0-56 (0.44-0-71)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">0-66 (0-55-0-80)</p></td>
</tr>
</tbody>
</table>
